JP2013520173A - インテグリンαｖβ８中和抗体 - Google Patents

インテグリンαｖβ８中和抗体 Download PDF

Info

Publication number
JP2013520173A
JP2013520173A JP2012554069A JP2012554069A JP2013520173A JP 2013520173 A JP2013520173 A JP 2013520173A JP 2012554069 A JP2012554069 A JP 2012554069A JP 2012554069 A JP2012554069 A JP 2012554069A JP 2013520173 A JP2013520173 A JP 2013520173A
Authority
JP
Japan
Prior art keywords
antibody
seq
disease
αvβ8
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012554069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520173A5 (cg-RX-API-DMAC7.html
Inventor
ステファン ニシムラ
チャンロン ルー
ジョディ リン バロン
ジェイムズ ディー． マルクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2013520173A publication Critical patent/JP2013520173A/ja
Publication of JP2013520173A5 publication Critical patent/JP2013520173A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
JP2012554069A 2010-02-18 2011-02-18 インテグリンαｖβ８中和抗体 Pending JP2013520173A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30574910P 2010-02-18 2010-02-18
US61/305,749 2010-02-18
US201061428814P 2010-12-30 2010-12-30
US61/428,814 2010-12-30
PCT/US2011/025514 WO2011103490A2 (en) 2010-02-18 2011-02-18 INTEGRIN αVβ8 NEUTRALIZING ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016079967A Division JP6212159B2 (ja) 2010-02-18 2016-04-13 インテグリンαｖβ８中和抗体

Publications (2)

Publication Number Publication Date
JP2013520173A true JP2013520173A (ja) 2013-06-06
JP2013520173A5 JP2013520173A5 (cg-RX-API-DMAC7.html) 2014-04-24

Family

ID=44483602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012554069A Pending JP2013520173A (ja) 2010-02-18 2011-02-18 インテグリンαｖβ８中和抗体
JP2016079967A Expired - Fee Related JP6212159B2 (ja) 2010-02-18 2016-04-13 インテグリンαｖβ８中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016079967A Expired - Fee Related JP6212159B2 (ja) 2010-02-18 2016-04-13 インテグリンαｖβ８中和抗体

Country Status (12)

Country Link
US (2) US9290572B2 (cg-RX-API-DMAC7.html)
EP (2) EP2536762A4 (cg-RX-API-DMAC7.html)
JP (2) JP2013520173A (cg-RX-API-DMAC7.html)
KR (1) KR101838763B1 (cg-RX-API-DMAC7.html)
CN (2) CN102834412B (cg-RX-API-DMAC7.html)
AU (1) AU2011217848B8 (cg-RX-API-DMAC7.html)
BR (1) BR112012020790B1 (cg-RX-API-DMAC7.html)
CA (1) CA2790488C (cg-RX-API-DMAC7.html)
MX (2) MX342270B (cg-RX-API-DMAC7.html)
RU (1) RU2565539C2 (cg-RX-API-DMAC7.html)
SG (1) SG183356A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011103490A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511686A (ja) * 2020-01-27 2023-03-22 メドイミューン・リミテッド 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012020790B1 (pt) * 2010-02-18 2021-09-28 The Regents Of The University Of California Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica
CA2846240C (en) * 2011-08-17 2021-01-12 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
US9657103B2 (en) * 2012-05-02 2017-05-23 New York University Methods of treating and preventing Staphylococcus aureus infections and associated conditions
EP2981554B1 (en) * 2013-04-01 2020-07-29 The Regents of The University of California Methods and compositions for treating and preventing disease associated with avb8 integrin
PL3157561T3 (pl) * 2014-06-17 2020-06-29 Medimmune Limited Ulepszone przeciwciała alfa-v beta-8
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
ES3023938T3 (en) 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
AU2019336197A1 (en) * 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
WO2020210650A1 (en) * 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
KR20220127858A (ko) 2020-01-15 2022-09-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 인테그린 avb8에 결합하는 항체 및 그의 용도
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
EP4594357A2 (en) * 2022-09-29 2025-08-06 The Brigham & Women's Hospital, Inc. Blocking itgb8 in neurodegenerative disease
WO2025038708A1 (en) * 2023-08-14 2025-02-20 Paragon Therapeutics, Inc. α4β7 INTEGRIN BINDING PROTEINS AND METHODS OF USE
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509562A (ja) * 2005-10-03 2009-03-12 キャンサー・リサーチ・テクノロジー・リミテッド αｖβ６ペプチドリガンド及びその活用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0575554A1 (en) * 1991-03-14 1993-12-29 Genentech, Inc. Novel beta integrin subunit
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
EP1049718B1 (en) * 1998-01-23 2006-04-05 MERCK PATENT GmbH Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
RU2401277C2 (ru) 2004-01-07 2010-10-10 Чирон Корпорейшн Не мышиное анти-m-csf-антитело (варианты), его получение и использование
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
ES2881353T3 (es) 2004-11-16 2021-11-29 Humanigen Inc Intercambio de casetes de la región variable de la inmunoglobulina
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
CA2735279A1 (en) 2008-08-29 2010-03-04 Symphogen A/S Anti-cd5 antibodies
BR112012020790B1 (pt) * 2010-02-18 2021-09-28 The Regents Of The University Of California Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica
CA2846240C (en) * 2011-08-17 2021-01-12 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509562A (ja) * 2005-10-03 2009-03-12 キャンサー・リサーチ・テクノロジー・リミテッド αｖβ６ペプチドリガンド及びその活用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6015016459; Ｊ．Ｃｅｌｌ　Ｂｉｏｌ．，２００２　Ａｐｒ　２９，１５７（３），ｐ．４９３-５０７，Ｅｐｕｂ　２００２　Ａｐｒ　２２ *
JPN6015016460; Ａｍ．Ｊ．Ｐａｔｈｏｌ．，２００３　Ａｕｇ，１６３（２），ｐ．５３３-４２ *
JPN6015016461; Ａｍ．Ｊ．Ｐａｔｈｏｌ．，２００５　Ｊｕｎ，１６６（６），ｐ．１８８３-９４ *
JPN6015016462; Ａｍ．Ｊ．Ｐａｔｈｏｌ．，２００９　Ｏｃｔ，１７５（４），ｐ．１３６２-７０，Ｅｐｕｂ　２００９　Ｓｅｐ　３ *
JPN6015050069; ナショナルバイオリソースプロジェクトにおける実費徴収および知的財産権の保護のあり方に関する報告書，２００ , ｐ．１７, ナショナルバイオリソースプロジェクト推進委員会　実 *
JPN6015050070; 科学技術動向，２００２　Ｓｅｐ，ｐ．１３-１９ *
JPN6015050071; Ｉｎｓｔｒｕｃｔｉｏｎｓ　ｆｏｒ　Ａｕｔｈｏｒｓ，Ｊｏｕｒｎａｌ　ｏｆ　Ｃｅｌｌ　Ｂｉｏｌｏｇｙ，［ｏｎｌｉｎｅ］，２０１５　Ｓｅｐ　８　ｕｐｄａｔｅｄ *
JPN6015050073; Ｊ　Ｃｅｌｌ　Ｓｃｉ．，２００９　Ｎｏｖ　１５，１２２（２２），ｐ．４００９-１１ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511686A (ja) * 2020-01-27 2023-03-22 メドイミューン・リミテッド 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体
JP7706458B2 (ja) 2020-01-27 2025-07-11 メディミューン リミテッド 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体

Also Published As

Publication number Publication date
RU2012139829A (ru) 2014-03-27
CN102834412A (zh) 2012-12-19
EP2536762A2 (en) 2012-12-26
KR101838763B1 (ko) 2018-03-14
US20130064837A1 (en) 2013-03-14
MX342270B (es) 2016-09-21
AU2011217848A8 (en) 2015-09-24
JP6212159B2 (ja) 2017-10-11
BR112012020790B1 (pt) 2021-09-28
SG183356A1 (en) 2012-09-27
CA2790488C (en) 2018-09-25
KR20120137482A (ko) 2012-12-21
US20160137737A1 (en) 2016-05-19
US9845357B2 (en) 2017-12-19
EP4219560A3 (en) 2023-08-23
AU2011217848B8 (en) 2015-09-24
MX2012009564A (es) 2013-01-29
CN102834412B (zh) 2016-01-20
CA2790488A1 (en) 2011-08-25
US9290572B2 (en) 2016-03-22
BR112012020790A2 (pt) 2016-05-03
AU2011217848B2 (en) 2015-08-27
MX375079B (es) 2025-03-06
RU2565539C2 (ru) 2015-10-20
JP2016196457A (ja) 2016-11-24
CN105315370A (zh) 2016-02-10
EP2536762A4 (en) 2014-01-01
AU2011217848A1 (en) 2012-09-13
WO2011103490A3 (en) 2011-10-27
EP4219560A2 (en) 2023-08-02
WO2011103490A2 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
JP6212159B2 (ja) インテグリンαｖβ８中和抗体
JP2022117998A (ja) Ｆｃ結合能を有する融合タンパク質を含む細胞外小胞の使用
JP6233933B2 (ja) 葉酸リセプターα及びβを認識する抗体
JP6093360B2 (ja) インテグリンα−ｖβ−８と結合する抗体
JP6037149B2 (ja) 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
JP2011509094A (ja) 炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト
JP6746701B2 (ja) 炎症性腸疾患の治療及び診断のための抗体
JP2010077026A (ja) がん関連マクロファージを標的とした固形がん治療剤
US20230159653A1 (en) Adam17 binding molecules and uses thereof
JP6925274B2 (ja) 治療
US20130230899A1 (en) Therapeutic agent for arteriosclerosis or arteriosclerotic disease, and diagnostic agent for arteriosclerosis or arteriosclerotic disease
HK1196971A (en) Antibodies that bind integrin alpha-v beta-8
HK1196971B (en) Antibodies that bind integrin alpha-v beta-8

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150423

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151214